Brief: Xeris Biopharma Says FDA Grants Orphan-Drug Exclusivity For Recorlev

Xeris Biopharma Holdings

30/01/2023 12:40

Jan 30 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ANNOUNCES FDA GRANTS ORPHAN-DRUG
EXCLUSIVITY FOR
RECORLEV®
    * XERIS BIOPHARMA HOLDINGS INC - XERIS IS ENTITLED TO SEVEN
YEARS
OF ORPHAN-DRUG MARKET EXCLUSIVITY FROM ITS FDA APPROVAL DATE OF
DECEMBER 30, 2021
    * XERIS BIOPHARMA-REGULATORY EXCLUSIVITY IN ADDITION TO
PATENT
EXCLUSIVITY UNDER U.S. PATENTS COVERING RECORLEV'STHERAPEUTIC
USE,EXTENDING TO MARCH 2040

Source text for Eikon:  ID:nBw3hMJFva 
Further company coverage:  XERS.O 
 ((Reuters.Briefs@thomsonreuters.com;))